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Abstract
Purpose: To investigate the use of a commercially available video-based EPID for in vivo dosimetry during treatment of prostate cancer
patients.
Methods: For 10 prostate cancer patients, the inter-fraction variation within measured portal dose images (PDIs) was assessed and
measured PDIs were compared with corresponding predicted PDIs based on the planning CT scan of the patient.
Results: For the lateral ®elds, the average standard deviation in the measured on-axis portal doses during the course of a treatment was
0.9%; for the anterior ®elds this standard deviation was 2.2%. The difference between the average on-axis measured portal dose and the
predicted portal dose was 0:3 ^ 2:1% (1 SD) for the lateral ®elds and 0:7 ^ 3:4% (1 SD) for the anterior ®elds. Off-axis differences between
measured and predicted portal doses were regularly much larger (up to 15%) and were caused by frequently occurring gas pockets inside the
rectum of the patients during treatment or during acquisition of the planning CT scan. The detected gas pockets did sometimes extend into the
gross tumour volume (GTV) area as outlined in the planning CT scans, implying a shift of the anterior rectum wall and prostate in the anterior
direction (internal organ motion).
Conclusions: The developed procedures for measurement and prediction of PDIs allow accurate dosimetric quality control of the treatment
of prostate cancer patients. Comparing measured PDIs with predicted PDIs can reveal internal organ motion. q 1998 Elsevier Science
Ireland Ltd. All rights reserved.
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1. Introduction
EPIDs have become a useful tool for the veri®cation and
correction of daily patient set-up during radiotherapy treat-
ment [5,6]. For this purpose, the position of bony structures
in a portal image, relative to the treatment ®eld, is compared
with their position in a corresponding simulator image or
digitally reconstructed radiograph (DRR).
Portal images also contain dosimetric information; the
pixel signals (grey scale values) in portal images are related
to the portion of radiation transmitted through the patient
and hence also related to the dose absorbed by the patient.
Several years ago investigations began to determine
whether the video-based SRI-100 EPID (Philips Medical
Systems, Crawley, UK) can be used for dosimetric treat-
ment veri®cation. The linearity and stability of this system
make it very suitable for dosimetric applications [8,12,14].
Since 1994, two of these EPIDs have been in daily use for
dosimetric quality control of the scanning photon beams of
our MM50 Racetrack Microtron (Scanditronix Medical,
Uppsala, Sweden) [8]. Recently, an algorithm has been
developed to convert a measured EPID image into an abso-
lute portal dose image (PDI), de®ned as the (transmitted)
dose distribution in the plane of the ¯uorescent screen of the
EPID located at 160 cm from the focus [12,20,22]. Also, a
method has been developed for the prediction of PDIs based
on the planning CT scan of the patient [11,21]. Comparing
PDIs obtained with the EPID during treatment with
predicted PDIs can reveal problems like incorrect (dosi-
metric) performance of the treatment unit, erroneous design,
production or application of compensators and deviations of
the patient anatomy during the daily treatment fractions
from the anatomy during acquisition of the planning CT
scan [30].
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This paper reports on our ®rst clinical experience with in
vivo dosimetry using an EPID. For the 10 prostate cancer
patients in this study, EPID images were acquired for all
treatment ®elds on every treatment day. The inter-fraction
(i.e. day-to-day) variation in measured PDIs was assessed
and measured PDIs were compared with a corresponding
predicted PDI which was calculated using the planning
CT scan of the patient. The obtained data suggest internal
organ motion due to observed gas pockets in the rectum of
the patients.
2. Materials and methods
2.1. Patients
Six out of 10 prostate cancer patients in this study parti-
cipated in a randomized trial, comparing conventional treat-
ment using rectangular ®elds with conformal treatment
using multi-leaf collimator (MLC) de®ned ®elds [15]. One
of the patients was treated after a prostatectomy. For all 10
patients a planning CT scan was acquired with a slice
distance of 5 mm. The patients were asked to retain a full
bladder at the time of acquisition of the planning CT scan
and during the daily treatments. No attempts were made to
control the rectal contents of the patients. For each patient
the visible prostate and the seminal vesicles were outlined
manually on all applicable CT slices by the radiation oncol-
ogist. The obtained gross tumour volume (GTV) [13] was
then extended automatically in three-dimensions (3D)
[24,25] with a margin of 15 mm, yielding the planning
target volume (PTV) [13]. The treatment plans were
designed with the CadPlan 3D treatment planning system
(TPS) (Varian-Dosetek, Espoo, Finland). All patients were
treated in the supine position with a three-®eld isocentric
technique consisting of one anterior and two lateral oblique
®elds that were partially delivered with a 608 wedge
inserted. The treatments were performed with the 25 MV
photon beam of an MM50 Racetrack Microtron. The dose
rate was 300 monitor units (MU) min21. A total dose of 66
Gy was prescribed to the isocentre and delivered in 33 frac-
tions. Apart from some minor underdosages (,2%) in small
parts of the superior and inferior ends of the PTV of some
patients, the treatment plans ful®lled the ICRU-50 recom-
mendations on dose homogeneity in the PTV [13]. (At
present, these underdosages are avoided by using intensity
modulated beams [9].)
During treatment, patient set-up was veri®ed and
corrected using an off-line correction protocol based on
analysis of the position of bony structures in EPID images
acquired in the non-wedged portion of each treatment ®eld
[5]. Using this protocol the standard deviation of systematic
and average random 3D set-up errors are as low as 1.5 and
2.0 mm, respectively. Prior to the analyses of measured
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Fig. 1. Schematic overview of the implemented dosimetric treatment veri-
®cation method (in vivo dosimetry) for comparison of measured and
predicted PDIs.
Table 1
On-axis inter-fraction variation in measured PDIs and average on-axis difference between measured and predicted PDIs for lateral and anterior ®elds separately
for 10 prostate cancer patients
Patient
number
Lateral ®eld Anterior ®eld
Difference
between measured
and predicted PDI
(%)
Inter-fraction
variation (1 SD)
(%)
Difference
between measured
and predicted PDI
(%)
Inter-fraction
variation (1 SD)
(%)
1 20.1 1.2 24.2 3.5
2 2.7 0.5 2.0 1.6
3 1.2 0.3 20.3 0.2
4 0.5 1.1 1.5 1.7
5 1.9 0.6 3.6 2.6
6 24.6 1.0 3.7 1.3
7 2.2 1.1 4.2 4.2
8 1.6 0.2 25.6 2.8
9 20.8 1.5 1.3 2.2
10 21.3 1.1 0.8 0.7
PDIs, the position of the bony structures in all daily
measured images was registered with the bony anatomy
visible in a corresponding DRR that was derived from the
planning CT scan of the patient.
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Fig. 2. Observed inter-fraction variations in measured PDIs for the right lateral treatment ®eld of patients 1 and 5±9. Each pixel represents the standard
deviation in the observed portal doses during the course of the treatment. The dashed BEV contours represent, from left to right, the rectum, the GTV including
prostate and seminal vesicles (not available for patient 1 because of prostatectomy) and the bladder. The presented iso-standard deviation contours connect
pixels with standard deviations of 2% and 3% for patients 1, 5 and 6. For patients 7±9 only the 3% contour is displayed because maximum standard deviations
in these images are larger than 4%.
2.2. In vivo dosimetry
For the patients in this study, EPID images were acquired
for all treatment ®elds on every treatment day and the inter-
fraction variation in measured PDIs was assessed. More-
over, measured PDIs were compared with a corresponding
predicted PDI calculated using the planning CT scan of the
patient; this procedure is schematically shown in Fig. 1.
Details on the prediction and measurement of PDIs are
discussed in Section 2.2.1 and Section 2.2.2.
2.2.1. PDI prediction
The ®xed focus-to-¯uorescent screen distance of the
applied EPID is 160 cm. Due to the resulting large air gap
between the patient and the EPID detector (35±55 cm) the
CadPlan TPS cannot be used for accurate prediction of PDIs
for this EPID. Therefore, we have developed our own algo-
rithms to predict PDIs using planning CT data of the patient
as input [11,16,21]. Primary photon contributions and
contributions from photons scattered from the patient onto
the EPID are calculated separately and are added to obtain
the PDI.
For calculation of the primary component, beam-harden-
ing effects, e.g. due to a ¯attening ®lter, a wedge or a
compensator, are taken into account. Scatter contribution
calculations are basically convolutions of the two-dimen-
sional beam ¯uence pro®le entering the patient with scatter
kernels, describing the scatter from the patient onto the
EPID. Basic input data for the calculations are obtained
from a set of transmission measurements through ¯at poly-
styrene absorbers for relevant absorber thicknesses, ®eld
sizes and distances to the EPID detector [21]. For a wide
range of inhomogeneous anthropomorphic phantoms and
treatment energies, predicted portal dose values and doses
measured with an ionization chamber agree within 1% (1
SD) [11,16,21].
2.2.2. PDI measurement
Portal images were acquired with a commercially avail-
able video-based SRI-100 EPID. This EPID basically
consists of a ¯uorescent screen, two mirrors and a charge
coupled device (CCD) camera [1,28]. In order to reduce
detection of high energy electrons generated inside the
patient, an extra 1 mm thick stainless steel plate was
mounted on top of the standard ¯uorescent screen, which
consists of a 1.65 mm thick stainless steel plate coated with
a ¯uorescent layer. The total water equivalent depth of the
EPID detector is only slightly smaller than the depth of
maximum dose of the applied 25 MV photon beam [22].
The extra build-up layer resulted in a minor decrease in
resolution but at the same time led to an increase of the
signal-to-noise ratio in portal images. Modi®cations to the
software of the SRI-100 system were performed at the level
of the macro command language that comes with the
system: (i) the standard image acquisition time was adjusted
to fully enclose the irradiation time in order to measure the
total delivered dose for each treatment ®eld (#58 MU, 12.8
s; 59±69 MU, 15.36 s; 70±86 MU, 19.2 s; 87±115 MU, 25.6
s; 116±173 MU, 38.4 s; 174±384 MU, 76.8 s) and (ii) for
dosimetric purposes, an additional raw 16-bit image was
saved to avoid digitization noise in low grey scale value
images [16,20,22]. Image enhancement procedures used to
obtain adequate image quality for patient set-up veri®cation
continued automatically after the raw image was saved.
With these modi®cations acquisition of portal images suita-
ble for in vivo dosimetry could be fully integrated into
existing imaging routines for patient set-up veri®cation
without introducing an increase in the overall treatment
time.
Visible photons produced by the X-ray beam in a point of
the ¯uorescent screen not only generate a signal in the corre-
sponding pixel of the EPID image, but also generate a
(much lower) signal in all other pixels. Heijmen et al. [12]
have shown that this is due to light scatter from components
within the EPID structure onto the CCD chip. PDIs are
derived from measured EPID images by removing the
contributions from scattered light to the pixel signals in an
EPID image using a deconvolution algorithm, as described
by Pasma et al. [20,22]. Using this method, derived PDIs
generally agree within 1% (1 SD) with ionization chamber
measurements in open, wedged and intensity modulated
beams for various anatomical phantoms.
2.3. EPID stability
During the study, the stability of the EPID response was
veri®ed on a 2-weekly basis by comparing the pixel signals
in acquired EPID images with measurements performed
with an ionization chamber array positioned at 100 cm
from the focus. Details on the applied set-up and equipment
are given in Ref. [8]. During the 4 month period of this
study, the variation in absolute on-axis EPID response
was 0.7% (1 SD). The variation in the EPID response rela-
tive to the on-axis measured grey scale value was less than
0.2% (1 SD). Both the observed variations in the absolute
on-axis response and in the relative off-axis response are in
agreement with the observations of Heijmen et al. [12] and
Dirkx et al. [8]. In the analyses of the inter-fraction variation
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Fig. 3. The blue, red and yellow contours represent the BEV contours of the rectum, the gross tumour volume and the bladder, respectively; point (0,0)
corresponds to the isocentre. (a) Observed inter-fraction variations (1 SD) in the measured portal doses for the right lateral ®eld of patient 8. (b) As in (a) but
now for the anterior ®eld. (c) Differences between the portal doses measured during fraction 13 of patient 8 for the right lateral ®eld and the corresponding
predicted portal doses. (d) As in (c) but now for the anterior ®eld. (e) Differences between the average measured PDI (average of 27 fractions) and the predicted
PDI for the right lateral ®eld of patient 8. (f) As in (e) but now for the anterior ®eld. The applied scale in (c) is different from the scale in (d±f) due to the large
deviations in portal dose as measured in fraction 13 in the lateral beam of patient 8.
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in the portal doses measured during patient treatment, the
reported standard deviations were obtained by subtracting
0.72 from the square of each measured standard deviation;
this corrected standard deviation is more directly correlated
with patient thickness variations.
3. Results and discussion
For each patient, acquisition of EPID images was planned
for all of the 33 treatment fractions. However, some portal
image acquisitions failed, e.g. because of accelerator inter-
locks or starting image acquisition too late, leaving about 30
successful acquisitions per treatment ®eld per patient.
3.1. On-axis portal doses
For each patient and for the lateral and anterior ®elds
separately, the on-axis inter-fraction variation in measured
PDIs and the average on-axis differences found between the
measured PDIs and the predicted PDI are presented in Table
1. For the lateral ®elds, the average standard deviation in the
on-axis measured portal doses was 0.9%. For the anterior
®elds the standard deviation was 2.2%. For the 10 patients,
the average difference between the on-axis measured portal
dose and the predicted portal dose was 0:3 ^ 2:1% (1 SD)
for the lateral ®elds and 0:7 ^ 3:4% (1 SD) for the anterior
®elds.
From the measured set of transmissions through ¯at
water-equivalent absorbers, as used for the PDI prediction
algorithm, relationships between radiological thicknesses
and portal doses were derived for typical lateral and anterior
treatment ®elds. A variation in radiological thickness of 1
cm, e.g. due to a variation in rectum and/or bladder ®lling,
results in a variation in the transmitted dose of approxi-
mately 1.9% for a lateral ®eld and 3.1% for an anterior
®eld. This difference between lateral and anterior ®elds is
an explanation for the observed larger standard deviations
for the anterior ®elds. Variations in the on-axis portal dose
could also be slightly higher for the anterior ®elds because
for these ®elds the central ray-line passes both the rectum
and the bladder, whereas the central ray-line of the lateral
®elds does not pass organs with a variable ®lling.
3.2. Off-axis portal doses
For the six patients with the largest inter-fraction varia-
tion in measured PDIs, the observed variations for the right
lateral ®eld are presented in Fig. 2, together with beam's-
eye-view (BEV) contours of the GTV (prostate 1 seminal
vesicles), the rectum and the bladder, as derived from the
planning CT scan. For patient 8, the inter-fraction variation
is also presented in colour in Fig. 3a. For the lateral ®elds,
areas with large variations (SD . 3%) are mainly found for
pixels corresponding to rays passing through the planned
position of the rectum, the superior/posterior portion of
the prostate and the posterior part of the seminal vesicles.
For rays passing only through the bladder, the observed
variations in measured portal doses are generally much
smaller. For the anterior ®elds, the areas with large varia-
tions are also strongly correlating with the BEV contour of
the rectum, as depicted in Fig. 3b for patient 8.
For those treatment fractions that show large differences
between measured and predicted PDIs, the deviations do
mostly occur in the areas of the PDI for which also large
inter-fraction variations are observed. For patient 8, differ-
ences between the PDI measured during fraction 13 and the
corresponding predicted PDI are presented in Fig. 3c,d for
the right lateral ®eld and the anterior ®eld, respectively. The
maximum difference between the measured and predicted
portal dose is 15%, indicating a difference in lateral radi-
ological pathlength with the planning CT scan of about 6
cm. Also for patient 8, Fig. 3e,f shows the difference
between the average measured PDI (average of 27 fractions)
and the predicted PDI for the right lateral ®eld and the
anterior ®eld, respectively.
3.3. Gas pockets and organ motion
Observed variations in both lateral and anterior measured
PDIs were often due to localized areas of increased portal
dose inside the rectum contour and the posterior part of the
GTV contour, indicating the presence of gas pockets inside
the rectum of the patients of variable size and shape. In the
presence of both faeces and a gas pocket, the gas is gener-
ally ¯oating on top of the faeces. In Fig. 3c,d, the red spots
inside the GTV contour are due to the presence of a large
gas pocket inside the rectum of patient 8 during treatment.
During acquisition of the planning CT scan, the rectum of
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Fig. 4. The planning CT scan of patient 8 used for PDI prediction. The
transversal slice shown contains the isocentre. The closed white contour
indicates the GTV volume and the dashed lines show the applied beams.
Notice the gas pocket inside the rectum.
patient 8 also contained a (smaller) gas pocket (see Fig. 4).
Due to this gas pocket, the differences between measured
and predicted portal doses inside the BEV contour of the
rectum in the lateral view (Fig. 3c) and on-axis differences
in the anterior view (Fig. 3d) are relatively small.
The presence of a large gas pocket within the BEV
contour of the GTV, as observed in the lateral ®eld (Fig.
3c), indicates internal organ motion. During fraction 13, the
positions of the prostate and seminal vesicles were in
disagreement with the planning CT scan. The gas pocket
in the rectum of the patient pushed both the anterior part of
the rectal wall and the GTV in an anterior direction, yielding
a risk for an unintended irradiation of a large part of the
rectum and for underdosing the anterior part of the GTV.
Similar observations were made for other fractions of
patient 8 and also for other patients.
For patient 8, Fig. 3e,f shows for each pixel the difference
between the average measured portal dose (average of 27
fractions) and the predicted portal dose for the right lateral
®eld and the anterior ®eld, respectively. The blue spots are
due to the presence of the gas pocket during acquisition of
the planning CT scan (Fig. 4). The deviations inside the
upper part of the GTV contour as presented in Fig. 3e indi-
cate the presence of gas pockets during treatment that
resulted in movement of the GTV in an anterior direction.
In recent years, several groups have studied internal
organ motion in prostate cancer patients [2±
4,7,17,19,23,26,27,29]. The observed prevalence in this
study of gas pockets occurring in the upper part of the
rectum close to the superior portion of the prostate and the
seminal vesicles (Figs. 2 and 3) is in agreement with the
presence of internal organ motion in these areas reported in
the literature, see e.g. Beard et al. [4] and van Herk et al.
[27].
For back-projection methods aiming at calculation of the
3D patient dose distribution from measured portal images
(see e.g. Hansen et al. [10] and McNutt et al. [18]), an
accurate 3D representation of the patient is required. In
this study, we have observed that large deviations between
measured and predicted portal doses were always due to
differences in patient anatomy during acquisition of the
planning CT scan and during the treatment fractions, due
to gas pockets in the rectum of the patients. In case of large
deviations between predicted and measured PDIs, calcula-
tion of the patient dose distribution based on the planning
CT scan would therefore have resulted in non-meaningful
dose distributions in the corresponding volumes in the
patients. In on-going studies we are investigating the applic-
ability of gas pockets visible in EPID images for on-line
geometrical veri®cation and correction of the position of
the prostate of the patient in the treatment beams. The
data presented in this paper do not allow the decision to
be made as to whether EPID images can be used for detec-
tion of internal organ motion due to variation in the amount
of faeces present in the rectum.
4. Conclusions
The small average on-axis differences between measured
and predicted PDIs and the variation therein indicate that the
developed methods and procedures allow accurate dosi-
metric quality control of the treatment of prostate cancer
patients in clinical practice. Large off-axis differences
between measured and predicted PDIs have been found to
correspond with frequently occurring gas pockets inside the
rectum of the patient during treatment or during acquisition
of the planning CT scan. In the case where a detected gas
pocket extends into the GTV area, as outlined in the plan-
ning CT scan, organ motion is evident.
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